Mohammed T. Abou-Saleh

532 PRINCIPLES AND PRACTICE OF GERIATRIC PSYCHIATRY12. Kane JM, Woerner M, Lieberman J. Epidemiological aspects oftardive dyskinesia. L’Ence´phale 1988; XIV: 191–4.13. Barnes TRE, Kidger T, Gore SM. Tardive dyskinesia: a 3-year followup study. Psychol Med 1983; 13: 71–81.14. Richardson MA, Casey DE. Tardive dyskinesia status: stability orchange. Psychopharmacol Bull 1988; 24: 471–5.15. Yagi G, Itoh H. Follow-up study of 11 patients with potentiallyreversible tardive dyskinesia. Am J Psychiat 1987; 144: 1496–8.16. Casey DE, Gardos G. Tardive dyskinesia: outcome at 10 years.Schizophren Res 1990; 3: 11.17. Yassa R, Lal S. Respiratory irregularity and tardive dyskinesia. ActaPsychiat Scand 1986; 73: 506–10.18. Gregory RP, Smith PT, Rudge P. Tardive dyskinesia presenting assevere dysphagia. J Neurol Neurosurg Psychiat 1992; 55: 1203–4.19. Feve A, Angelard B, Lacau-St-Guily J. Laryngeal tardive dyskinesia.J Neurol 1995; 242: 455–9.20. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiat 2000;61(4): 27–32.21. Jeste DV, Caligiuri MP, Paulsen JS et al. Risk of tardive dyskinesia inolder patients. A prospective longitudinal study of 266 outpatients.Arch Gen Psychiat 1995; 52: 756–65.22. Jeste DV, Lacro JP, Palmer B et al. Incidence of tardive dyskinesia inearly stages of low-dose treatment with typical neuroleptics in olderpatients. Am J Psychiat 1999; 156: 309–11.23. Glazer WM. Review of the incidence studies of tardive dyskinesiaassociated with typical antipsychotics. J Clin Psychiat 2000; 61(4):15–20.24. Smith JM, Baldessarini RJ. Changes in prevalence, severity andrecovery in tardive dyskinesia with age. Arch Gen Psychiat 1980; 37:1368–73.25. Jus A, Pineau R, Lachance R et al. Epidemiology of tardivedyskinesia. Part I. Nerv Syst 1976; 37: 210–14.26. Woerner MG, Alvir JMJ, Saltz BL et al. Prospective study of tardivedyskinesia in the elderly: rate and risk factors. Am J Psychiat 1998;155: 1521–8.27. Saltz BL, Woerner MM, Kane JM et al. Prospective study oftardive dyskinesia incidence in the elderly. J Am Med Assoc 1991;266: 2402–6.28. Jeste DV, Jeste SD, Wyatt RJ. Reversible tardive dyskinesia:implications for therapeutic strategy and prevention of tardivedyskinesia. In Bannet J, Belmaker RH, eds, New Directions inTardive Dyskinesia Research, Vol 21. Basel: Karger, 1983: 34–48.29. Domino EF, Kovacic B. Monkey models of tardive dyskinesia. InBannet J, Belmaker RH, eds, New Directions in Tardive DyskinesiaResearch, Vol 21, Basel: Karger, 1983: 21–33.30. Crane GE, Smeets RA. Tardive dyskinesia and drug therapy ingeriatric patients. Arch Gen Psychiat 1974; 30: 341–3.31. Toenissen LM, Casey DE, McFarland BH. Tardive dyskinesia in theaged. Arch Gen Psychiat 1985; 42: 278–84.32. Labbate LA, Lande RG, Jones F, Oleshansky MA. Tardivedyskinesia in older out-patients: a follow-up study. Acta PsychiatScand 1997; 96: 195–8.33. Caligiuri MP, Lacro JP, Rockwell E et al. Incidence and risk factorsfor severe tardive dyskinesia in older patients. Br J Psychiat 1997;171: 148–53.34. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: anoverview. Am J Psychiat 1981; 138: 297–309.35. Jeste DV, Rosenblatt JE, Wagner RL et al. High serum neurolepticlevels in tardive dyskinesia (letter). N Engl J Med 1979; 301: 1184.36. Yesavage JA, Holman CA, Becker J et al. Correlation of age andacute thiothixene levels. Psychopharmacology 1981; 74: 117–20.37. Barnes TRE, McPhillips MA. Critical analysis and comparison of theside-effect and safety profiles of the new antipsychotics. Br J Psychiat1999; 174(38): 34–43.38. Maixner SM, Mellow AM, Tandon R. The efficacy, safety andtolerability of antipsychotics in the elderly. J Clin Psychiat 1999;60(8): 29–41.39. Jeste DV, Rockwell E, Harris MJ et al. Conventional vs. newerantipsychotics in elderly patients. Am J Geriat Psychiat 1999; 7: 70–6.40. Madhusoodanan S, Suresh P, Brenner R, Pilai R. Experience with theatypical antipsychotics—risperidone and olanzapine in the elderly.Ann Clin Psychiat 1999; 11: 113–18.41. Barak Y, Wittenberg N, Naor S et al. Clozapine in elderly psychiatricpatients: tolerability, safety, and efficacy. Comp Psychiat 1999; 40:320–5.42. Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in olderadults. Pharmacotherapy 1999; 19: 811–22.43. Tariot PN. The older patient: the ongoing challenge of efficacy andtolerability. J Clin Psychiat 1999; 60(23): 29–33.44. Jeste DV, Lacro JP, Bailey A et al. Lower incidence of tardivedyskinesia with risperidone compared with haloperidol in olderpatients. J Am Geriat Soc 1999; 156: 309–11.45. Jeste DV, Okamoto A, Napolitano J et al. Low incidence of persistenttardive dyskinesia in elderly patients with dementia treated withrisperidone. Am J Psychiat 2000; 157: 1150–5.46. Davidson M, Harvey PD, Vervarcke J et al. A long-term, multicentre,open-label study of risperidone in elderly patients with psychosis. IntJ Geriat Psychiat 2000; 15: 506–14.47. Street JS, Clark WS, Gannon KS et al. Olanzapine treatment ofpsychotic and behavioural symptoms in patients with Alzheimerdisease in nursing care facilities. Arch Gen Psychiat 2000; 57: 968–76.48. Siede H, Muller HR. Choreiform movements as side effects ofphenothiazine medication in geriatric patients. J Geriat Soc 1967; 15:517–22.49. Kennedy PF, Hershon HI, McGuire RJ. Extrapyramidal disordersafter prolonged phenothiazine therapy. Br J Psychiat 1971; 118:509–18.50. Smith JM, Kucharski LT, Oswald WT et al. A systematicinvestigation of tardive dyskinesia in inpatients. Am J Psychiat1979; 136: 918–22.51. Smith JM, Kucharski LT, Eblen C et al. An assessment of tardivedyskinesia in schizophrenic outpatients. Psychopharmacology 1979;64: 99–104.52. Smith JM, Dunn DD. Sex differences in the prevalence of severetardive dyskinesia. Am J Psychiat 1979; 136: 1080–2.53. Ramsay FM, Millard PH. Tardive dyskinesia in the elderly. AgeAgeing 1986; 15: 1145–50.54. O’Keane V, Dinan TG. Orofacial dyskinesia and senile dementia ofthe Alzheimer type. Int J Geriat Psychiat 1991; 6: 41–5.55. Richardson MA, Pass R, Craig TJ et al. Factors influencing theprevalence and severity of tardive dyskinesia. Psychopharmacol Bull1984; 20: 33–8.56. Hruska RE, Silbergeld EK. Estrogen treatment enhances dopaminereceptor sensitivity in the rat striatum. Eur J Pharmacol 1980; 61:397–400.57. Glazer WM, Naftolin F, Moore DC. The relationship of circulatingestradiol to tardive dyskinesia in men and postmenopausal women.Psychoneuroendocrinology 1983; 8: 429–34.58. Dávila R, Andia I, Miller JC et al. Evidence of low dopaminergicactivity in elderly women with spontaneous orofacial dyskinesia. ActaPsychiat Scand 1991; 83: 1–3.59. Barnes TRE, Liddle PF. Tardive dyskinesia: implications forschizophrenia? In Schiff AA, Roth M, Freeman HL, eds,Schizophrenia: New Pharmacological and Clinical Development.London: Royal Society of Medicine Services, 1985: 81–7.60. Barnes TRE. Tardive dyskinesia: risk factors, pathophysiology andtreatment. In Granville-Grossman K, ed., Recent Advances in ClinicalPsychiatry, Vol 6. London: Churchill Livingstone, 1988: 185–207.61. Waddington JL. Schizophrenia, affective psychoses, and otherdisorders treated with neurobiological determinants, and theconflict of paradigms. Int Rev Neurobiol 1989; 31: 297–353.62. Hunter R, Earl CJ, Thornicroft S. An apparently irreversiblesyndrome of abnormal movements following phenothiazinemedication. Proc R Soc Med 1964; 54: 758–62.63. Crane GE, Paulson G. Involuntary movements in a sample of chronicmental patients and their relation to the treatment with neuroleptics.Int J Neurol 1967; 3: 286–91.64. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primarypsychiatric diagnosis. Psychosomatics 1984; 25: 135–8.65. Edwards H. The significance of brain damage in oral dyskinesia. Br JPsychiat 1970; 116: 271–5.66. Villeneuve A, Turcotte J, Bouchard M et al. Release phenomena anditerative activities in psychiatric geriatric patients. Can Med Assoc J1974; 110: 147–53.67. Davis K, Berger P, Hollister L. Tardive dyskinesia and depressiveillness. Psychopharmacol Commun 1976; 2: 125.